Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study
Although severe anemia was more common in patients with renal impairment, the efficacy of treatment did not differ, indicating that pemetrexed remains a viable treatment option for this population with proper management.
Authors
- Hitomi Ajimizu (ORCID: https://orcid.org/0000-0001-6625-7464)
- Hironori Yoshida (ORCID: https://orcid.org/0000-0002-1676-0173)
- Kazutaka Hosoya (ORCID: https://orcid.org/0000-0002-7864-897X)
- Hiroshi Yoshida (ORCID: https://orcid.org/0000-0001-6456-8648)
- Toyohiro Hirai (ORCID: https://orcid.org/0000-0002-7431-9044)
- Kentaro Hashimoto (ORCID: https://orcid.org/0000-0002-3116-2411)
- Tatsuya Ogimoto (ORCID: https://orcid.org/0009-0000-5202-2330)
- Hiroaki Ozasa (ORCID: https://orcid.org/0000-0002-5315-3751)
- Takashi Nomizo (ORCID: https://orcid.org/0000-0002-4328-3042)
- Keiichiro Suminaga
- Tomoko Funazo (ORCID: https://orcid.org/0000-0003-2152-2150)
- Yusuke Shima
Institutions
- Kyoto University (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1186/s12885-025-13785-x
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52